Ariste Medical Develops Drug-Eluting Mesh For More Effective Open Hernia Repair

Share Article

Technology Presented at the Americas Hernia Society Annual Meeting Will Enable Significantly Reduced Infection Rates and Improved Patient Outcomes

Ariste Medical Logo

“Adding antibiotics to implantable medical devices will help preserve their function and increase the likelihood of successful patient recovery for millions of people worldwide.”

Ariste Medical today revealed new research outlining the company’s novel method for addressing medical device failure in open ventral hernia repair. With more than 350,000 procedures performed annually, ventral hernia repair is among the most common surgeries in the United States, but often results in high rates of infection, excess morbidity and healthcare expenses. Ariste’s patented formulations enable a drug-eluting polypropylene mesh that prevents contamination of implantable surgical devices by delivering targeted agents to affected areas.

Data presented at the 17th Annual Hernia Repair Meeting of the Americas Hernia Society demonstrate sustained antimicrobial activity of the Ariste mesh against common bacteria for at least 14 days, as well as protection against a broad spectrum of bacterial pathogens associated with mesh surgical site infections, such as MRSA and E.coli. Additional drug targets allow this technology to reduce restenosis (scar tissue formation) and thrombosis (blood clotting).

“Ariste’s new generation of technology is poised to make a significant impact in open ventral hernia repair by drastically reducing bacterial colonization of surgical implants that are so often devastating to patients and care providers,” said Ariste Medical Chief Scientific Officer Lisa K. Jennings, PhD. “Adding antibiotics to implantable medical devices will help preserve their function and increase the likelihood of successful patient recovery for millions of people worldwide.”

To date, three preclinical studies have been completed and four peer-reviewed papers published describing drug elution from the surface of surgical devices, including polypropylene (PP) and expanded polytetrafluoroethylene (ePTFE). In one preclinical study using a rapamycin-surgical graft, restenosis was reduced by 68 percent. In another using antimicrobials, minocycline and rifampin, bacterial colonization was reduced by 99.9 percent. Ariste’s formulations work well with various implantable materials, making them applicable for many other devices as well.

Ariste Medical was founded by Drs. Timothy Fabian and Lisa Jennings, internationally-recognized faculty at The University of Tennessee Health Science Center (UTHSC), and Brian Best, an experienced leader in biotechnology and pharmaceutical development. For more information regarding Ariste Medical and its products, visit http://www.aristemedical.com/ or call 901-866-1400.

About Ariste Medical

Ariste Medical is a preclinical stage company that develops drug-eluting surgical implants to prevent common causes of device failure, thereby improving patient outcomes and reducing costs of care. Founded in 2007 by experienced leaders in the fields of biotechnology, vascular biology and vascular surgery, Ariste is currently developing a drug-eluting mesh for open ventral hernia repair. Other targeted clinical areas include additional implantable mesh products for hernia repair, catheters and peripheral bypass grafts. Each of these products will help address common causes of device failure, such as infection, restenosis and thrombosis. For more information regarding Ariste Medical, visit http://www.aristemedical.com/ or call 901-866-1400.

###

Press Contact
Ariste Medical PR
Kristi McCain, (385) 204-4341
mccainconsultingllc(at)gmail(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kristi McCain
Ariste Medical
+1 (385) 204-4341
Email >
Visit website